Since PKD1 was previously characterized as a negative regulator of cell motility, our data suggest that a PKD1 reexpression strategy may be used as a therapeutic approach to reduce or prevent breast cancer cell metastasis. This evidence concerns the gene PKD1 and breast carcinoma.